Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 17.04 USD 0.95%
Market Cap: 252.2m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one ANIK stock under the Base Case scenario is 28.86 USD. Compared to the current market price of 17.04 USD, Anika Therapeutics Inc is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANIK Relative Value
Base Case
28.86 USD
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
78
Median 3Y
2.3
Median 5Y
2.9
Industry
8.1
Forward
1.6
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-15.3
Industry
23
Forward
-6.4
vs History
60
vs Industry
0
Median 3Y
43.2
Median 5Y
41.4
Industry
23.4
vs History
6
vs Industry
Median 3Y
-21.1
Median 5Y
16.9
Industry
27.3
vs History
71
vs Industry
45
Median 3Y
1.5
Median 5Y
1.7
Industry
2.6
vs History
96
vs Industry
69
Median 3Y
1.9
Median 5Y
2.4
Industry
8.1
Forward
1.2
vs History
92
vs Industry
63
Median 3Y
3.1
Median 5Y
4
Industry
9.6
vs History
vs Industry
Median 3Y
-34.6
Median 5Y
-10.7
Industry
4.3
Forward
7.4
vs History
vs Industry
Median 3Y
-14.1
Median 5Y
-8.9
Industry
3.8
Forward
-108.5
vs History
60
vs Industry
1
Median 3Y
35.7
Median 5Y
31.4
Industry
6
vs History
11
vs Industry
Median 3Y
77.5
Median 5Y
20.9
Industry
3.8
vs History
76
vs Industry
48
Median 3Y
1.4
Median 5Y
1.5
Industry
4.8

Multiples Across Competitors

ANIK Competitors Multiples
Anika Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Anika Therapeutics Inc
NASDAQ:ANIK
252.1m USD 1.5 -2.6 -10.5 -6.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
US
Anika Therapeutics Inc
NASDAQ:ANIK
Average P/E: 211.8
Negative Multiple: -2.6
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Anika Therapeutics Inc
NASDAQ:ANIK
Average EV/EBITDA: 17.9
Negative Multiple: -10.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Anika Therapeutics Inc
NASDAQ:ANIK
Average EV/EBIT: 23.2
Negative Multiple: -6.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top